Skip to main content
Fig. 2 | Cell Communication and Signaling

Fig. 2

From: Single-cell RNA sequencing reveals enhanced antitumor immunity after combined application of PD-1 inhibitor and Shenmai injection in non-small cell lung cancer

Fig. 2

Combination therapy strengthened the antitumor effect and alleviated side effects in the humanized mouse model. (A) The schedule of survival experiment in the humanized mouse model. IgG: immunoglobulin G isotype control; PD-1: PD-1 immune-checkpoint blockade antibody; SMI: SMI monotherapy; PD-1+SMI: combination of anti-PD-1 and SMI. (B) Percentage of survival of mouse during different treatments (n = 7). **P < 0.01. (C) The schedule of tumor volume measurement experiment in the humanized mouse model. (D) The tumor volume of different treatments on Day 43. *P < 0.05, **P < 0.01. A mouse in the PD-1 group died on Day 32. IgG, SMI, and PD-1 + SMI groups, n = 7; PD-1 group, n = 6. (E) The changes of tumor volume depicted during different treatments. (F) Representative photographs of tumors after the different treatments on Day 43. (G) The alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in the different treatments

Back to article page

Cell Communication and Signaling

ISSN: 1478-811X